Dexsiometheptene mucate - Tonix Pharmaceuticals

Drug Profile

Dexsiometheptene mucate - Tonix Pharmaceuticals

Alternative Names: Dexisometheptene mucate - Tonix Pharmaceuticals; TNX 201

Latest Information Update: 19 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tonix Pharmaceuticals Inc
  • Class Alkenes; Antimigraines; Methylamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Tension type headache

Most Recent Events

  • 01 Feb 2016 Discontinued - Phase-II for Tension headache in USA (PO)
  • 01 Feb 2016 Tonix Pharmaceuticals completes a phase II trial in Tension headache in USA (NCT02423408)
  • 08 Dec 2015 Tonix Pharmaceuticals completes enrolment in a phase II trial in Tension headache in USA (9188674; NCT02423408)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top